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Abstract
Background: Recent reports indicate that over the next decade rates of chronic obstructive
pulmonary disease (COPD) in women will exceed those in men in the western world, though in
most jurisdictions, women continue to smoke less compared with men. Whether female adult
smokers are biologically more susceptible to COPD is unknown. This study reviewed the available
evidence to determine whether female adult smokers have a faster decline in forced expiratory
volume in one second (FEV1) compared with male adult smokers and whether age modifies the
relationship between cigarette smoke and lung function decline.
Methods: A systematic review and a meta-analysis was performed of population-based cohort
studies that had a follow-up period of at least 3 years, measured FEV1 on at least two different time
points, and presented FEV1 data stratified by gender and smoking status in adults.
Results: Of the 646 potentially relevant articles, 11 studies met these criteria and were included
in the analyses (N = 55 709 participants). There was heterogeneity in gender-related results across
the studies. However, on average current smokers had a faster annual decline rate in FEV1%
predicted compared with never and former smokers. Female current smokers had with increasing
age a significantly faster annual decline in FEV1% predicted than male current smokers (linear
regression analysis, R2 = 0.56; p = 0.008). Age did not materially affect the rate of decline in FEV1%
predicted in male and female former and never smokers (p = 0.775 and p = 0.326, respectively).
Conclusion: As female smokers age, they appear to experience an accelerated decline in FEV1%
predicted compared with male smokers. Future research powered specifically on gender-related
changes in lung function is needed to confirm these early findings.
Background
Chronic obstructive pulmonary disease (COPD) is a
major cause of death in North America and Europe and
the only major disease for which the morbidity and mor-
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tality are still increasing in these continents [1,2].
Although COPD is currently the 4th-leading cause of mor-
tality and the 12th-leading cause of disability, by the year
2020 it will be the 3rd-leading cause of death and the 5th-
leading cause of disability worldwide [3,4]. Strikingly, this
projected increase in COPD-related morbidity and mor-
tality will be driven largely by the female population, a
trend that started 20 years ago [5]. Some have ascribed
this trend to increased smoking rates in women over the
past two decades [6]. However, there are likely to be other
factors involved. While female smoking rates have indeed
increased relative to male rates since the 1970's, female
smoking rates continue to be lower than those for men
[5,7]. For example, in the US in 2003, 19% of adult
women smoked versus 24% of adult men [8]. Moreover,
even when women smoke, they consume on average
fewer cigarettes per day and have lower serum cotinine
levels compared with men, indicating that cigarette smoke
exposure per se cannot account for the rising COPD bur-
den in women [9]. These data raise the possibility that
female smokers may be biologically more susceptible to
COPD compared to male smokers. We conducted a sys-
tematic review and a meta-analysis to determine whether
female smokers do or do not have increased susceptibility
to COPD compared with male smokers. Additionally,
since age is a major determinant of changes in lung func-
tion [10], we sought to determine whether age modified
the relationship between smoking and lung function
decline in both men and women.
Methods
Search for relevant studies
Using PUBMED (1966–January 2006) and EMBASE
(1980–January 2006) electronic databases, we conducted
a comprehensive literature search to identify studies
related to the decline of lung function published before
January 2006. We used lung function sensitive terms
(forced expiratory volume, vital capacity) combined with
design sensitive terms (cohort studies, longitudinal stud-
ies, follow-up studies, prospective studies), and smoking
sensitive terms (smoke, cigarette, smoking) in our
searches. The electronic searches were supplemented by
scanning of the reference lists from retrieved articles to
identify additional studies that may have been missed
during the electronic search. We also contacted the pri-
mary authors of retrieved studies for additional data and/
or clarification of data, where necessary.
Study selection and data abstraction
The primary objective of this study was to compare the
annual decline of lung function, measured as percent pre-
dicted forced expiratory volume in one second (FEV1 %
pred), which is an important phenotype of COPD [11],
between men and women stratified according to smoking
status. To mitigate methodological biases, we limited our
search to studies that: (1) were population-based; (2)
employed a longitudinal cohort design; (3) had a follow-
up of at least 3 years; (4) measured FEV1 on at least two
different time points; and (5) presented FEV1 data strati-
Table 1: Characteristics of studies included in meta-analyses*
Source Project name Sample size Women (%) Average age at 
baseline (year)
Duration of follow 
up (year)
Viegi et al,22 2001 Po River Delta Epidemiologic Study, 
North Italy
1774 51 32 8
Chinn et al,12 2005 European Community Respiratory 
Health Survey II, 27 centers, 26 were in 
western Europe and one was in the 
USA
6654 51 34 9
Rijcken et al,13 1995 Vlagtwedde-Vlaardingen study in the 
Netherlands
1619 43 39 25
Jedrychowski et al,14 
1986
Cracow Study in Cracow, Poland 1364 64 40 13
James et al,15 2005 Busselton Health Study in Busselton, 
Western Australia
9317 51 42 29
Tashkin et al,16 1984 UCLA Population Studies in Los 
Angeles County, USA
2401 54 46 5
Sherrill et al,17 1996 Tucson Epidemiology Study of 
Obstructive Lung Disease in Tucson, 
Arizona, USA
477 41 48 8
Connett et al,23 2003† Lung Health Study, 10 centres, nine in 
the USA, one in Canada
5346 37 48 5
Xu et al,18 1992 Six Cities Study in the USA 12 080 55 49 6
Vestbo et al,19 1996 Copenhagen City Heart Study, 
Denmark
9435 57 53 5
Griffith et al,20 2001 Cardiovascular Health Study in the USA 5242 57 73 7
Symbols: *: Order in table: average age at baseline; †: The participants were smokers with mild-to-moderate COPD.Respiratory Research 2006, 7:52 http://respiratory-research.com/content/7/1/52
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fied by gender and smoking status. We excluded cross-sec-
tional studies, or studies that evaluated occupational
exposures on lung function. We also excluded studies
whose primary focus was on secondhand smoke expo-
sures. From each retrieved article, two independent inves-
tigators abstracted the following information: project
name, sample size, average age at baseline, proportional-
ity of women, duration of follow up, and annual decline
rate of FEV1 % pred stratified by gender and smoking sta-
tus (Table 1, Table 2). Any questions or discrepancies
regarding these data were resolved through iteration and
consensus.
Statistical analysis
We used the annual change in the rate of FEV1% pred
reported in the studies to conduct the primary analyses.
Annual changes in FEV1% pred were calculated by sub-
tracting the final FEV1% pred from the baseline value and
dividing the difference by the number of years of follow-
up. For studies that only provided absolute FEV1 values
[12-20], we calculated FEV1% pred by applying a pub-
lished prediction equation to the absolute values [21].
The reported baseline mean age and height were used in
these calculations. For studies that did not report data on
the subjects' height [12,14,17-19], we imputed 174 cm for
men and 161 cm for women because the populations of
these studies had similar race and age profiles as those
reported in James's study (Table 2) [15]. We compared the
annual changes in FEV1% pred between women and men
across smoking status by using male values as the referent.
A positive value denoted a larger decline in women, while
a negative value denoted a larger decline in men. We
hypothesized that age might be an important modifier for
the relationship between smoking and gender-related
decline in lung function since the incidence of obstructive
airways disease in women increases sharply in the post-
menopausal period [5]. We used both unweighted and
weighted linear regression techniques to assess gender-
related differences in the annual decline of FEV1% pred. In
the weighted analysis, we used the sample size of men and
women in each smoking category as the weights. All tests
were two-tailed in nature and were performed using statis-
tical software SAS (version 9.1, SAS Institute, Carey, N.C).
Results
A summary of the search strategy is shown in Figure 1. The
original search yielded 466 and 180 citations in PUBMED
and EMBASE, respectively. The abstracts of these articles
were selected and reviewed. Of these, 67 articles were
retrieved for a detailed review. After excluding studies that
used identical cohorts (n = 41) and studies that had insuf-
ficient data (n = 15), we were left with 11 original studies
that met the inclusion criteria. The baseline characteristics
of these studies are summarized in Table 1. Collectively,
there were 55 709 participants in these studies, 52% were
women, and the baseline average age of the cohorts varied
from 32 to 73 years. The duration of follow-up ranged
from 5 to 29 years.
Table 2 summarizes the annual decline in FEV1% pred in
both men and women according to smoking status. In
general, older cohorts experienced a faster decline in
FEV1% pred/yr compared with younger cohorts and cur-
rent smokers had a faster decline in FEV1% pred/yr com-
pared with never smokers. Former smokers had similar
decline rates in FEV1% pred/yr as never smokers. There
were four studies that provided data on lung function
changes stratified by the mean daily consumption of ciga-
Table 2: Annual decline rate in FEV1% pred/yr in men and women according to smoking status
Source Average age at 
baseline (year)
Never smokers Former smokers Current smokers
Women Men Difference* Women Men Difference* Women Men Difference*
Viegi et al,22 2001 32 NA NA NA -0.12 -0.21 0.09 0.12 0.13 -0.01
C hinn et al,12 2005 34 0.78 0.76 0.02 0.91 0.76 0.15 0.88 0.84 0.04
Rijcken et al,13 1995 39 0.83 0.96 -0.13 0.89 0.87 0.02 0.97 1.11 -0.14
Jedrychow ski et 
al,14 1986
40 1.35 1.13 0.22 NA NA NA 1.41 1.46 -0.05
James et al,15 2005 42 0.87 0.91 -0.04 0.99 1.01 -0.02 1.05 1.22 -0.17
Tashkin et al,16 
1984
46 1.51 1.70 -0.19 1.36 1.65 -0.29 1.97 2.15 -0.18
Sherrill et al,17 1996 48 0.50 0.44 0.06 0.49 0.85 -0.36 0.66 0.49 0.17
Connett et al,23 
2003
48 NA NA NA 0.37 0.07 0.30 1.20 1.05 0.15
Xu et al,18 1992 49 1.08 0.98 0.10 1.11 0.89 0.22 1.42 1.37 0.05
Each cell represents annual change in FEV1% pred/yr, unless otherwise indicated.
Symbols: *:A positive number denotes a larger decline in FEV1% pred in women; a negative number denotes a large decline in FEV1% pred in men; †: 
Never smokers and former smokers were combined as non-smokers in the article since they did not differ in FEV1% pred decline.Respiratory Research 2006, 7:52 http://respiratory-research.com/content/7/1/52
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rettes [15,18,19,22]. There was a dose-dependent acceler-
ation in the decline of FEV1% pred/yr (Table 3).
In current smokers, with increasing age, women had a sig-
nificantly faster decline in FEV1% pred/yr compared with
men (R2 = 0.56; p = 0.008), while in former and never
smokers, age did not significantly modify the rate of
decline in FEV1% pred/yr between men and women (p =
0.775 and p = 0.326, respectively) (Figure 2). There were
no material differences in the results between the
weighted and unweighted analyses. The three average age-
difference in FEV1% pred/yr regression lines diverged at
~45 to 50 years of age. As a sensitivity assessment, we
repeated the analysis after excluding the study by Griffith
and colleagues [20], which appeared to an outlier in Fig-
ure 3. In the sensitivity analysis, female compared with
male smokers still had a faster decline in FEV1% pred/yr
(R2 = 0.40; p = 0.050), while in former smokers and never
smokers, there were no gender differences (in former
smokers, R2 = 0.14; p = 0.323; in never smokers, R2 = 0.28
and p = 0.179).
Discussion
The present systematic review indicates that female com-
pared with male smokers experienced a faster decline in
lung function beyond age 45 to 50 years. This trend was
evident even in female smokers who smoked only a mod-
est amount of cigarettes (<15 g/day). In non- or ex-smok-
ers, there were no significant gender-related changes in
FEV1% pred over time. However, there was considerable
heterogeneity in the results across the studies (see table 2
and figure 3) and as such these data should be interpreted
cautiously. Additional prospective longitudinal studies
powered specifically on gender-related changes in lung
function in the post-menopausal age group are needed to
confirm these observations.
The findings from the present study are consistent with
other studies, which were not included in this review [21-
29]. Prescott and colleagues reported similar findings
from two independent population samples: Copenhagen
City Heart Study (CCHS) and Glostrup Population Stud-
ies (GPS) [24]. In both samples, when adjusted for pack-
years of smoking, female smokers had a faster decline in
lung function compared with male smokers. In the CCHS,
the estimated excess loss of FEV1 was 7.4 ml per pack-year
in female current smokers and 6.3 ml per pack-year in
male current smokers. In the GPS, the estimated excess
loss of FEV1 was 10.5 ml per pack-year in the female cur-
rent smokers and 8.4 ml per pack-year in the male current
smokers. Importantly, in both samples, even after adjust-
Table 3: Annual decline rate in FEV1% pred/yr for female and male current smokers stratified by the daily amount of cigarette 
consumption
Source Average age at 
baseline (year)
Never smokers < 15 g/day 15 g/day
Women Men Difference* Women Men Difference* Women Men Difference*
Viegi et al,22 2001 32 NA NA NA 0.08 0.12 -0.04 0.22 0.15 0.07
James et al,15 2005 42 0.87 0.91 -0.04 0.97 1.12 -0.15 1.13 1.26 -0.13
Xu et al,18 1992 49 1.08 0.98 0.10 1.16 0.97 0.19 1.51 1.44 0.07
Vestbo et al,1 1996 53 1.00 0.83 0.17 1.23 0.98 0.25 1.32 1.22 0.10
Total -- 0.99 0.91 0.08 1.10 0.95 0.15 1.35 1.23 0.12
Each cell represents annual change in FEV1% pred, unless otherwise indicated.
Symbols: *: A positive number denotes a larger decline in FEV1% pred in women; a negative number denotes a larger decline in FEV1% pred in men.
Flow diagram of study selection Figure 1
Flow diagram of study selection.
Search results: N=646
PUBMED: n=466
EMBASE:  n=180
Did not meet criteria 
or duplicate articles:
n=579
Studies retrieved: 
n=67
Identical cohort used: n=41
Insufficient data: n=15
Studies included in analyses: n=11Respiratory Research 2006, 7:52 http://respiratory-research.com/content/7/1/52
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ments of daily tobacco consumption and years of smok-
ing, female smokers had a higher risk of hospitalization
for COPD compared with male smokers (relative risk, RR,
1.5, 95% confidence interval, CI, 1.2–2.1 in the CCHS
and RR, 3.6, 95% CI, 1.4–9.0 in the GPS) [24]. Further-
more, women with impaired lung function (FEV1 < 40%
pred) had a higher risk of death from all causes (RR, 5.0
for women, 2.7 for men) and of deaths from obstructive
lung diseases (RR, 57 for women, 34 for men,) compared
with men [25]. Xu and colleagues studied 1 618 male and
1 669 female adults aged 40–69 yrs in the Beijing Respira-
tory Health Study [28]. Although female never smokers
had better lung function than did male never smokers,
female current smokers had significantly lower lung func-
tion compared with male smokers [28]. In a genetics study
of early onset COPD, Silverman and colleagues found that
female first-degree current or ex-smoking relatives of the
probands were almost two times more likely to demon-
strate mild airflow limitation (FEV1 <80% predicted) and
over three times more likely to have severe airflow limita-
tion (FEV1 <40% predicted) than did male relatives [29].
Although the present study did not evaluate effects of
smoking cessation on lung function in men and women,
data from the Lung Health Study indicates that female
quitters may experience larger gains in lung function than
do male sustained quitters. In that study, female sustained
quitters experienced a 2.5 fold larger improvement in
FEV1% pred than did male sustained quitters after one
year of smoking cessation [30]. These data, in conjunction
with results of the present systematic review, suggest that
female smokers have increased susceptibility for COPD,
Unweighted analysis of the relationship between age and gender-related differences in the annual decline in FEV1% pred  according to smoking status Figure 2
Unweighted analysis of the relationship between age and gender-related differences in the annual decline in 
FEV1% pred according to smoking status Abbreviation: FEV1: forced expiratory volume in one second.
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especially after age 45 to 50 years. With smoking cessa-
tion, however, female quitters may experience a larger
recovery of their lung function than do male quitters.
Although our study was not designed to evaluate the
effects of smoking in adolescent youths, previous studies
indicate that smoking may also have a greater (negative)
impact on lung growth in female than male youngsters.
Gold et al [31] found that among adolescents, smoking
five or more cigarettes a day, as compared with never
smokers, was associated with a 1.09% per year reduction
in the growth rate of FEV1 in girls, while for boys, smoking
reduced FEV1 growth by only 0.20%/yr. Patel et al [27]
found that exposure to cigarette smoke during childhood
was an independent risk factor for the development of
obstructive airways disease in women but not in men.
Thus, the relationship between gender, age and FEV1
changes may be U-shaped.
The mechanisms responsible for the increased susceptibil-
ity of women to cigarette smoke are largely unknown.
There is now a general consensus that inflammation is at
the heart of the pathobiology of COPD and that the
inflammatory process involves both the lung (airways and
parenchyma) and the systemic circulation [32-34]. The
intensity of the inflammatory process in the airways and
in the systemic circulation is associated with severity of
FEV1  impairment [33,34]. Whether women are more
likely to demonstrate airway inflammation compared
with men is unknown. Interestingly, women in the gen-
eral population are known to have higher circulating C-
reactive protein levels, a marker of systemic inflamma-
Weighted analysis of the relationship between age and gender-related differences in the annual decline in FEV1% pred for cur- rent smokers Figure 3
Weighted analysis of the relationship between age and gender-related differences in the annual decline in 
FEV1% pred for current smokers The regression line is weighted by the numbers of current smokers. The diameter of 
each circle is proportional to the number of current smokers in each study. Abbreviation: FEV1: forced expiratory volume in 
one second.
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tion, but only after ~50 years of age [35]. Since active
smoking amplifies systemic inflammation, independent
of other factors [36], smoking-inflammation pathway
may be an important contributor to the increased risk
observed in women in the peri and post-menopausal peri-
ods. Further research is needed to confirm this hypothesis.
Another potential mechanism may relate to bronchial
hyperresponsiveness. In the Lung Health Study, there was
a higher prevalence of bronchial hyperresponsiveness
among women than among men (85% in women versus
59% of the men) [37]. In another population-based
study, Leynaert and coworkers demonstrated increased
prevalence of bronchial hyperresponsiveness in women,
even after adjustments for respiratory symptoms, atopy,
or lung function parameters [38]. Paoletti et al [39] also
found increased risk of bronchial hyperresponsiveness
among women compared with men independent of base-
line lung function. In women, they observed that current
smokers had significantly more reactive airways than did
non- or ex-smokers. However, in men, smoking status
made no material impact on bronchial responsiveness
[39]. These data may be clinically relevant since bronchial
hyperresponsiveness has been associated with increased
risk of both COPD progression [40] and COPD mortality
[41].
Additionally, cigarette smoke may modify hormonal sta-
tus in women, which may affect lung function. Women
who are active smokers become relatively estrogen defi-
cient compared with non-smokers because cigarette
smoke induces cytochrome P450 isoenzymes CYP1A1
and CYP1A2, which alter estrogen metabolism leading to
increased production of inactive catechols [42]. Hormone
replacement therapy in the post-menopausal period is
associated with improved lung function, reducing the risk
of airflow obstruction by ~25% [43]. Hormone replace-
ment therapy also reduces bronchial hyperresponsiveness
in post-menopausal women [44].
An alternative hypothesis for higher susceptibility of
females to smoking may be differences in lung develop-
ment between females and males. Interestingly, relative to
male rates, female rates of obstructive airway diseases
increase sharply during adolescence [45]. Before pubes-
cence, girls have smaller lung volumes than do boys but
generate higher flows [46]. During teenage years, airways
and lung volumes demonstrate isotropic growth in boys.
In girls, however, airway growth becomes disproportion-
ately smaller relative to lung volume growth, indicating
dysanapsis [47]. Thus, for any given lung volume and size,
women have smaller airways compared with men, which
may make the airways more susceptible to the adverse
effects of cigarette smoke.
There were several limitations to the study. Firstly, we
used only a crude marker of smoking (i.e. self-report of
smoking). Since male smokers generally smoke more cig-
arettes than do female smokers and have a longer smok-
ing history, we may have underestimated the true effects
of cigarette smoking in the female population [9]. Sec-
ondly, as with most systematic reviews, publication bias is
a source of concern. Figure 3 indicates that there were no
material differences in results between large and small
studies, suggesting that publication bias did not signifi-
cantly affect the results.
Conclusion
We found that beyond age 45 to 50 years, female smokers
appear to experience an accelerated decline in FEV1%
pred/yr compared with male smokers. Additional pro-
spective longitudinal studies powered specifically on gen-
der-related changes in lung function in the post-
menopausal age group are needed to confirm these obser-
vations. In view of the growing incidence of smoking and
the COPD in the female population, there is an urgent
need to promote smoking abstinence and cessation in the
female population.
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